Clinical trials: Mild and Moderate Alzheimer's Disease
Alzheimer Disease
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
To access the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00498602
- Testing
- ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline
- Where
- 27 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
This is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety, effects on the body, and blood, CSF, and urine drug…
- Trial name
- NCT01795339
- Testing
- AZD3293
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
To Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease
With the enrichment of living environment and the progress of medicine, the scale of aging population has increased in many countries of the world.
- Trial name
- NCT03656042
- Testing
- Filgrastim (75mcg/0.3ml)
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer's Disease
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ARGO (NCT01350362)
- Testing
- tideglusib
- Where
- 6 sites in Belgium, Finland and 4 more
- Volunteers
- 306 people
- Sponsor
- Noscira SA
Alzheimer's Disease
Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease
- Trial name
- NCT01009255
- Testing
- GSK239512
- Where
- 35 sites in Bulgaria, Chile and 6 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's…
- Trial name
- NCT05811442
- Testing
- 50561 high dose, 50561 low dose
- Where
- 12 sites in China
- Volunteers
- 68 people
- Sponsor
- Beijing Joekai Biotechnology LLC
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
The Connection Study is a six-month confirmatory Phase 3 study to determine the safety and efficacy of Dimebon in the treatment of mild-to-moderate Alzheimer's disease (AD).
- Trial name
- CONNECTION (NCT00675623)
- Testing
- Dimebon
- Where
- 28 sites in United States
- Volunteers
- 598 people
- Sponsor
- Medivation, Inc.
Alzheimer's Disease
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission…
- Trial name
- SUMMIT AD (NCT01254773)
- Testing
- Experimental Bapineuzumab
- Where
- 28 sites in United States
- Volunteers
- 146 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer Disease
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor [donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)] for at least 3 months, and…
- Trial name
- NCT00551161
- Testing
- memantine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwell Health
Alzheimer's Disease
Efficacy, Safety and Response Predictors of Astragalus Membranaceus on the Improvement of Cognitive Function in Mild-to-Moderate Alzheimer's Disease
Alzheimer's disease (AD), the most common cause of dementia, is characterized by cognitive impairment, mental and behavioural abnormalities, and social dysfunction.
- Trial name
- NCT05578443
- Testing
- 10g Astragalus, Routine treatment, 20g Astragalus
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Fujian Medical University Union Hospital
Alzheimer Disease
A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients with Alzheimer's disease.
- Trial name
- NCT00035204
- Testing
- galantamine
- Volunteers
- 63 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease (AD)
Alzheimer's Disease Treated With Vagus Nerve Stimulation
The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's…
- Trial name
- Advant (NCT06923007)
- Testing
- Vagus Nerve Stimulation
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Mild to Moderate Alzheimer's Disease
Study of LM11A-31-BHS in Mild-moderate AD Patients
The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS
- Trial name
- NCT03069014
- Testing
- 400mg LM11A-31-BHS, 800mg LM11A-31-BHS
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 242 people
- Sponsor
- PharmatrophiX Inc.
Mild Dementia, Moderate Dementia
The Effects of a Park Visit Program on Individuals With Dementia and Their Caregivers
The overall goals of our project is to understand the effects of participating in park visits and nature-based activities for people living with dementia and their caregivers.
- Conditions
- Mild Dementia, Moderate Dementia, Alzheimer Disease
- Trial name
- NCT05527587
- Testing
- Nature Connections Intervention
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Dementia, Alzheimer Type
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease.
- Trial name
- NCT00154635
- Testing
- DCB-AD1
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Alzheimer Disease
Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to assess whether SAM-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00481520
- Testing
- SAM-531
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer's Disease
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01690195
- Testing
- ABT-126
- Where
- 39 sites in United States, Canada and 5 more
- Volunteers
- 343 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.